Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2S,3S)-3-amino-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxo-2-(trans-4-[1,2,4]triazolo[1,5-a]pyridin-5-ylcyclohexyl)butanamide
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This compound is an experimental small molecule inhibitor of dipeptidyl peptidase IV (DPP-IV or DPP4), an enzyme involved in the degradation of incretin hormones such as GLP‑1. By inhibiting DPP-IV activity with high potency and selectivity (IC50 = low nanomolar range), it increases endogenous levels of active incretins and thereby enhances insulin secretion in response to meals. The compound was developed as a potential oral treatment for type 2 diabetes mellitus. It demonstrates good oral bioavailability and efficacy in preclinical models but does not have evidence of clinical approval or advanced development status[7][3].
- Other names
- (2S,3S)-3-amino-4-(3S)-3-fluoropyrrolidin-1-yl-N,N-dimethyl-4-oxo-2-(trans 4-[1,2,4]triazolo[1,5-a]pyridin 5 ylcyclohexyl)butanamide(2S,3S)-3-amino-4-(3S)-fluoropyrrolidin 1 yl N,N dimethyl 4 oxo 2 (trans 41,24 triazolo15 a pyridin51 yclohexyl) butanamideCHEMBL209710CHEMBL-209710CHEMBL 209710CHEMBL1198534CHEMBL-1198534CHEMBL 1198534
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on (2S,3S)-3-amino-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxo-2-(trans-4-[1,2,4]triazolo[1,5-a]pyridin-5-ylcyclohexyl)butanamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (2S,3S)-3-amino-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxo-2-(trans-4-[1,2,4]triazolo[1,5-a]pyridin-5-ylcyclohexyl)butanamide.